Search

Displaying results 361 - 370 of 661 in total
  1. Drug

    AVXS-301

    go.drugbank.com/drugs/DB17943
    Experimental

    AVXS-301 consists of an adeno-associated virus serotype 9 (AAV9) designed to express the superoxide dismutase 1 (SOD1) gene.

  2. Drug

    Dextropropoxyphene

    go.drugbank.com/drugs/DB00647
    ApprovedIllicitWithdrawn

    Due to the risk of cardiac arrhythmias and overdose, possibly leading to death, dextropropoxyphene has been withdrawn from the market in Europe and the United States.

  3. Drug

    Sipavibart

    go.drugbank.com/drugs/DB21908
    ApprovedInvestigational

    [A274088] It was later approved in Europe in January 2025 and in Canada in March 2025.

  4. Drug

    Adrafinil

    go.drugbank.com/drugs/DB08925
    ApprovedWithdrawn

    It was marketed in France and elsewhere in Europe under the trade name Olmifon until September 2011 when France's FDA equivalent reassessed the drug and withdrew marketing permission.

  5. Drug

    Sibutramine

    go.drugbank.com/drugs/DB01105
    ApprovedIllicitWithdrawn

    Sibutramine (trade name Meridia in the USA, Reductil in Europe and other countries), usually as sibutramide hydrochloride monohydrate, is an orally administered agent for the treatment of obesity.

  6. Drug

    Magnesium carbonate

    go.drugbank.com/drugs/DB09481
    Approved

    Magnesium carbonate, also known as magnesite, is a common over the counter remedy for heartburn and upset stomach caused by overproduction of acid in the stomach [FDA Label].

    Mixtures: CITRATO ESPRESSO GABBIANI, CITRATO ESPRESSO GABBIANI
  7. Drug

    Tislelizumab

    go.drugbank.com/drugs/DB14922
    ApprovedInvestigational

    This approval was based on positive results demonstrated in the RATIONALE 302 study, where an 8.6-month median overall survival rate was observed for tislelizumab treatment compared to 6.3-month for chemotherapy

  8. Drug

    Clofarabine

    go.drugbank.com/drugs/DB00631
    ApprovedInvestigational

    It is marketed as Clolar in the U.S. and Canada, or Evoltra in Europe, Australia, and New Zealand.

  9. Drug

    Omalizumab

    go.drugbank.com/drugs/DB00043
    ApprovedInvestigational

    [A39518] Omalizumab was first approved in the US in 2003 [A263507] and in Europe in 2005.

  10. Drug

    Octinoxate

    go.drugbank.com/drugs/DB09496
    ApprovedInvestigational

    Octinoxate is a cinnamate ester and common ingredient in sunscreen and other skin care products to minimize DNA photodamage. It was originally developed in 1950's as an organic UV-B filter that absorbs UV-B rays from sun. It is often com...

    Mixtures: Cyzone Express Your Face, Tan Express Dark Tanning Awesome Oil SPF 4Products: Sei Bella Age-Defying Liquid Foundation Espresso, Expression Marine